摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-methyl-5-chloro-phenylhydrazine | 94447-40-2

中文名称
——
中文别名
——
英文名称
2-methyl-5-chloro-phenylhydrazine
英文别名
(5-Chloro-2-methylphenyl)hydrazine
2-methyl-5-chloro-phenylhydrazine化学式
CAS
94447-40-2
化学式
C7H9ClN2
mdl
MFCD00086667
分子量
156.615
InChiKey
XVFXJNWHUFWYMQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    38
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2928000090

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS INHIBITEURS DE JAK À LA PYRAZOLOPYRIMIDINE ET PROCÉDÉS
    申请人:GENENTECH INC
    公开号:WO2010051549A1
    公开(公告)日:2010-05-06
    The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient. Ia
    这项发明提供了Formula Ia的JAK激酶抑制剂,其对映体、二对映体或其药学上可接受的盐,其中R1、R2、R7和Z在此处被定义,包括Formula Ia化合物和药学上可接受的载体、辅料或载体的药物组合物,以及治疗或减轻对JAK激酶活性抑制有响应的疾病或病况的方法。
  • PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    申请人:Blaney Jeffrey
    公开号:US20120022043A1
    公开(公告)日:2012-01-26
    The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.
    该发明提供了Formula Ia的JAK激酶抑制剂,其对映体、二对映体或其药学上可接受的盐,其中R1、R2、R7和Z在此处定义,包括Formula Ia化合物和药学上可接受的载体、辅料或载体的药物组合物,以及治疗或减轻对JAK激酶活性抑制有响应的疾病或病况的方法。
  • [EN] PREPARATION OF 3-AMINOALKYL-SUBSTITUTED INDOLE DERIVATIVES FROM PHENYLHYDRAZINES AND AMINOKETONES<br/>[FR] PREPARATION DE DERIVES D'INDOLE A SUBSTITUTION 3-AMINOALKYLE A PARTIR DE PHENYLHYDRAZINES ET D'AMINOCETONES
    申请人:SUVEN LIFE SCIENCES LTD
    公开号:WO2004041781A1
    公开(公告)日:2004-05-21
    The present invention relates to a process for the preparation of indole derivatives, particularly those, which are useful as pharmaceutical intermediates. The process involves formation of hydrazone derivative between a phenyl hydrazine and a ketone amine, followed by cyclisation to give desired 2,3-substituted indole derivative in the presence of acid catalyst.
    本发明涉及一种制备吲哚衍生物的方法,特别是那些作为药物中间体有用的衍生物。该方法涉及在酸催化剂存在下,通过苯基肼和酮胺之间的缩醛衍生物的形成,然后进行环化反应,得到所需的2,3-取代吲哚衍生物。
  • [EN] 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS FOR THE TEATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS DE 1,5-DIHYDRO-PYRAZOLO(3,4-D)PYRIMIDIN-4-ONE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE PDE9A POUR LE TRAITEMENT DE TROUBLES DU SNC
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2009068617A1
    公开(公告)日:2009-06-04
    The invention relates to novel substituted pyrazolopyrimidines. Chemically, the compounds are characterised by general Formula (I): with R1 being phenyl or pyridyl, any of which is substituted with 1 to 4, preferably 1 to 3 substituents X; X independently of each other being selected from C2-C6-alky1 or Ci-C6-alkoxy, where C2-C6-alkyl and C1-C6-alkoxy are at least dihalogenated up to perhalogenated. preferably with 2 to 6 halogen substituents, and the halogen atoms being selected from the group of fluoro, chloro and bromo, preferably fluoro; R2 being phenyl or heteroaryl, where phenyl is substituted by 1 to 3 radicals and heteroaryl is optionally substituted by 1 to 3 radicals in each case independently of one another selected from the group of C1-C6-alkyI, C1-C6- alkoxy, hydroxycarbonyl, cyano, trifluoromethyl, amino, nitro, hydroxy, C1-C6- alkylamino, halogen, C6-C10-arylcarbonylamino, C1-C6-alkylcarbonylamino, C1- C6-alkylaminocarbonyl. C1-C6-alkoxycarbonyl, C6-C10-arylaminocarbonyl, heteroarylaminocarbonyl. heteroarylcarbonylamino, C1-C6-alkylsulphonyl- amino, C1-C6-alkylsulphonyl and C1-C6-alkylthio; The new compounds shall be used for the manufacture of medicaments, in particular medicaments for improving, perception, concentration, learning and/or memory in patients in need thereof.
    该发明涉及新型取代吡唑吡嘧啶化合物。从化学角度来看,这些化合物的特征由一般式(I)表示:其中R1为苯基或吡啶基,其中任一取代为1到4个,优选为1到3个取代基X;X独立地选自C2-C6-烷基或C1-C6-烷氧基,其中C2-C6-烷基和C1-C6-烷氧基至少经过二卤化至全卤化处理,最好具有2到6个卤素取代基,卤素原子选自氟、氯和溴,最好为氟;R2为苯基或杂环烷基,其中苯基取代为1到3个基团,杂环烷基可选择性地取代为1到3个基团,每种基团独立地选自C1-C6-烷基、C1-C6-烷氧基、羟基羰基、氰基、三氟甲基、氨基、硝基、羟基、C1-C6-烷基氨基、卤素、C6-C10-芳基羰胺基、C1-C6-烷基羰胺基、C1-C6-烷氨基羰基、C1-C6-烷氧羰基、C6-C10-芳基氨基羰基、杂环烷基氨基羰基、杂环烷基羰胺基、C1-C6-烷基磺酰氨基、C1-C6-烷基磺酰基和C1-C6-烷基硫基;这些新化合物可用于制备药物,特别是用于改善患者的感知、注意力、学习和/或记忆的药物。
  • Palladium-Catalyzed Direct Denitrogenative C-3-Arylation of 1<i>H</i>-Indoles with Arylhydrazines using Air as the Oxidant
    作者:Yongxin Chen、Shuaibo Guo、Kangning Li、Jinpeng Qu、Hua Yuan、Qiuru Hua、Baohua Chen
    DOI:10.1002/adsc.201200997
    日期:2013.3.11
    A novel palladium‐catalyzed approach to direct C‐3‐arylation of 1H‐indoles with arylhydrazines using air as the oxidant via CN bond cleavage has been developed. Various substituents are tolerated in this system in moderate to good yields. This reaction could also be compatible with a larger scale. Thus, this strategy using arylhydrazines as arylating reagents provides a powerful method for constructing
    一种新颖的钯催化的方法来直接C-3芳基化的1 ħ使用空气作为氧化剂芳基肼-indoles经由Ç  N键裂解已经研制成功。在该系统中,各种取代基以中等到良好的产率被容许。该反应也可以与更大的规模相容。因此,这种使用芳基肼作为芳基化试剂的策略为构建取代的3-芳基-1 H-吲哚提供了一种有力的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐